Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie S Callander

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Ejhaem|August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessationRebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
Blood|August 24, 2011
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneShaji K Kumar, Hajime Uno, Susanna J Jacobus, et al.
Frontiers in Oncology|October 24, 2022
Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysisMuhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2015
Single-molecule analysis reveals widespread structural variation in multiple myelomaAditya Gupta, Michael Place, Steven Goldstein, et al.
Leukemia|November 21, 2021
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapiesSusan Bal, Ehsan Malek, Ankit Kansagra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2017
Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal CancerChelsea Hope, Philip B Emmerich, Athanasios Papadas, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 2, 2017
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Lakeesha L Carmichael, KyungMann Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
Frontiers in Immunology|October 20, 2022
Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysisMuhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Ejhaem|August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessationRebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
Blood|August 24, 2011
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneShaji K Kumar, Hajime Uno, Susanna J Jacobus, et al.
Frontiers in Oncology|October 24, 2022
Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysisMuhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2015
Single-molecule analysis reveals widespread structural variation in multiple myelomaAditya Gupta, Michael Place, Steven Goldstein, et al.
Leukemia|November 21, 2021
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapiesSusan Bal, Ehsan Malek, Ankit Kansagra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 30, 2017
Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal CancerChelsea Hope, Philip B Emmerich, Athanasios Papadas, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 2, 2017
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Lakeesha L Carmichael, KyungMann Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.
Frontiers in Immunology|October 20, 2022
Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysisMuhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, et al.
Pageof 10